CD274 and neoplasm: Nivolumab (Opdivo) is a PD-1-binding IgG4 immunoglobulin that acts as an immune checkpoint inhibitor by selectively blocking the interaction between PD-1 expressed on activated T cells, and its ligands PD-L1 or PD-L2 expressed on immune cells and tumor cells.